Moving to eCOA is not only more patient-centric, but regulators like the FDA are also recommending eCOA over traditional, paper-based methods because of the clear benefits in terms of data accuracy. Learn more about the key ways in which eCOA works to help all study stakeholders produce better data.

Encouraging broad patient inclusivity throughout drug development is one thing, but understanding the “why” behind the “how” is another. The FDA has stepped up here, too, recently issuing patient-focused drug development (PFDD) guidance documents that provide a framework for ensuring all patient needs are being met, including those historically marginalized by the healthcare system.

There are many obstacles that prevent people from enrolling in clinical trials. Travel time, distance to trial sites and lack of trial awareness are a few of the primary examples. Find out how decentralized clinical trials can help sponsors expand their pool of potential trial participants while also increasing diversity within their clinical trials.